Pathobiochemical signatures of cholestatic liver disease in bile duct ligated mice

BackgroundDisrupted bile secretion leads to liver damage characterized by inflammation, fibrosis, eventually cirrhosis, and hepatocellular cancer. As obstructive cholestasis often progresses insidiously, markers for the diagnosis and staging of the disease are urgently needed. To this end, we compiled a comprehensive data set of serum markers, histological parameters and transcript profiles at 8 time points of disease progression after bile duct ligation (BDL) in mice, aiming at identifying a set of parameters that could be used as robust biomarkers for transition of different disease progression phases.ResultsStatistical analysis of the more than 6,000 data points revealed distinct temporal phases of disease. Time course correlation analysis of biochemical, histochemical and mRNA transcript parameters (=factors) defined 6 clusters for different phases of disease progression. The number of CTGF-positive cells provided the most reliable overall measure for disease progression at histological level, bilirubin at biochemical level, and metalloproteinase inhibitor 1 (Timp1) at transcript level. Prominent molecular events exhibited by strong transcript peaks are found for the transcriptional regulator Nr0b2 (Shp) and 1,25-dihydroxyvitamin D(3) 24-hydroxylase (Cyp24a1) at 6 h. Based on these clusters, we constructed a decision tree of factor combinations potentially useful as markers for different time intervals of disease progression. Best prediction for onset of disease is achieved by fibronectin (Fn1), for early disease phase by Cytochrome P450 1A2 (Cyp1a2), passage to perpetuation phase by collagen1α-1 (Col1a1), and transition to the progression phase by interleukin 17-a (Il17a), with early and late progression separated by Col1a1. Notably, these predictions remained stable even for randomly chosen small sub-sets of factors selected from the clusters.ConclusionOur detailed time-resolved explorative study of liver homogenates following BDL revealed a well-coordinated response, resulting in disease phase dependent parameter modulations at morphological, biochemical, metabolic and gene expression levels. Interestingly, a small set of selected parameters can be used as diagnostic markers to predict disease stages in mice with cholestatic liver disease.

[1]  Jangsun Baek,et al.  A modified correlation coefficient based similarity measure for clustering time-course gene expression data , 2008, Pattern Recognit. Lett..

[2]  T. Scherstén,et al.  Bile acid concentrations in systemic and portal serum in presumably normal man and in cholestatic and cirrhotic conditions. , 1977, Scandinavian journal of gastroenterology.

[3]  Andrew Leask,et al.  All in the CCN family: essential matricellular signaling modulators emerge from the bunker , 2006, Journal of Cell Science.

[4]  Ricardo J. G. B. Campello,et al.  On the selection of appropriate distances for gene expression data clustering , 2014, BMC Bioinformatics.

[5]  W. Jochum,et al.  Characterization of time‐related changes after experimental bile duct ligation , 2008, The British journal of surgery.

[6]  Sabine Weiskirchen,et al.  Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis , 2015, Journal of visualized experiments : JoVE.

[7]  E. Petricoin,et al.  Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example , 2013, PloS one.

[8]  A. Geerts,et al.  Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation , 2008, International journal of experimental pathology.

[9]  R. Orlando,et al.  Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes , 2013, PloS one.

[10]  V. Paradis,et al.  Expression of connective tissue growth factor in experimental rat and human liver fibrosis , 1999, Hepatology.

[11]  A. Gressner,et al.  Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[12]  A. Tanaka,et al.  Gene expression profiling in whole liver of bile duct ligated rats: VEGF‐A expression is up‐regulated in hepatocytes adjacent to the portal tracts , 2007, Journal of gastroenterology and hepatology.

[13]  R. Heuckeroth,et al.  Transcriptional profiling after bile duct ligation identifies PAI‐1 as a contributor to cholestatic injury in mice , 2005, Hepatology.

[14]  Ramesh Ramakrishnan,et al.  High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array , 2008, PloS one.

[15]  Gary R. Grotendorst,et al.  Connective tissue growth factor is directly related to liver fibrosis. , 2002, Hepato-gastroenterology.

[16]  S. Friedman,et al.  Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[17]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.

[18]  D. Adams,et al.  Immune interactions in hepatic fibrosis. , 2008, Clinics in liver disease.

[19]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[20]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[21]  C. Eipel,et al.  Hepatoprotection in bile duct ligated mice mediated by darbepoetin-α is not caused by changes in hepatobiliary transporter expression. , 2013, International journal of clinical and experimental pathology.

[22]  K. Okazaki,et al.  Effect of biliary obstruction and internal biliary drainage on hepatic cytochrome P450 isozymes in rats. , 2008, World journal of gastroenterology.

[23]  D. Schuppan,et al.  Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. , 2001, The American journal of pathology.

[24]  C. Trautwein,et al.  The Chemokine CCL3 Promotes Experimental Liver Fibrosis in Mice , 2013, PloS one.

[25]  D. Goltz,et al.  Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis , 2010, Fibrogenesis & tissue repair.

[26]  D. Brigstock,et al.  Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[27]  D. Brenner,et al.  Anti-fibrogenic strategies and the regression of fibrosis. , 2011, Best practice & research. Clinical gastroenterology.

[28]  H. Fujii,et al.  Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. , 2013, The Journal of surgical research.

[29]  Ricardo J. G. B. Campello,et al.  Proximity Measures for Clustering Gene Expression Microarray Data: A Validation Methodology and a Comparative Analysis , 2013, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[30]  R. Schwabe,et al.  Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.

[31]  B. Copple,et al.  E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr‐1/SHP/EID1 network , 2014, Hepatology.

[32]  F. Tacke,et al.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.

[33]  B. A. Schacter,et al.  Effect of cholestasis produced by bile duct ligation on hepatic heme and hemoprotein metabolism in rats. , 1983, Gastroenterology.

[34]  Y. Yılmaz,et al.  Concentrations of Connective Tissue Growth Factor in Patients with Nonalcoholic Fatty Liver Disease: Association with Liver Fibrosis , 2012, Disease markers.

[35]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[36]  E. Park,et al.  Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. , 2013, Gastroenterology.

[37]  Y. Inagaki,et al.  Emerging insights into Transforming growth factor β Smad signal in hepatic fibrogenesis , 2007, Gut.

[38]  Hartmut Jaeschke,et al.  Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. , 2013, Toxicology and applied pharmacology.

[39]  V. Sundaram,et al.  Atypical causes of cholestasis. , 2014, World journal of gastroenterology.

[40]  M. Peters,et al.  Growth factor and procollagen type I gene expression in human liver disease. , 1995, Gastroenterology.

[41]  P. Dent,et al.  Down-regulation of Cholesterol 7α-Hydroxylase (CYP7A1) Gene Expression by Bile Acids in Primary Rat Hepatocytes Is Mediated by the c-Jun N-terminal Kinase Pathway* , 2001, The Journal of Biological Chemistry.

[42]  C. Meyer,et al.  Transforming Growth Factor-β (TGF-β)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation* , 2013, Journal of Biological Chemistry.

[43]  K. Irvine,et al.  The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease , 2014, Hepatology.

[44]  M. Karsdal,et al.  Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats , 2013, Front. Physiol..

[45]  R. Goldschmeding,et al.  Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.